JPMorgan Forecasts GLP-1 Market in China, India, and Brazil to Reach $22 Billion by 2035

JPMorgan projects the GLP-1 weight-loss and diabetes drug market across China, India, and Brazil to surge to $22 billion by 2035, up from its current valuation of $7 billion.
The forecast highlights significant long-term expansion potential for drugmakers and telehealth providers operating in emerging markets, including Eli Lilly ($LLY), Novo Nordisk ($NVO), and Hims & Hers Health ($HIMS).